Acumen Closes First Round of Financing; Dr. Mark Cochran Joins Board

SOUTH SAN FRANCISCO, California March 31, 2005 -Acumen Pharmaceuticals announced today that it successfully closed its first financing. The company raised a total of $1.2 million, 20% more than expected. The investors include NeuroVentures LLC, certain angel investors, and the Biotechnology Value Fund. The company issued convertible notes with a 12-month maturity that will convert into Series A one-for-one. In concert with this financing, Dr. Mark Cochran of NeuroVentures was invited to join the Acumen Board of Directors.

Acumen will use the proceeds to finance the ongoing antibody program, advance the company's patent portfolio, and pursue a significant pharmaceutical alliance.